about
Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.Assessing treatment efficacy in the subset of responders in a randomized clinical trial.EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation.
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Analysis of duration of response in oncology trials.
@en
Analysis of duration of response in oncology trials.
@nl
type
label
Analysis of duration of response in oncology trials.
@en
Analysis of duration of response in oncology trials.
@nl
prefLabel
Analysis of duration of response in oncology trials.
@en
Analysis of duration of response in oncology trials.
@nl
P2093
P1476
Analysis of duration of response in oncology trials.
@en
P2093
Kevin J Carroll
Kristine Pemberton
Stuart Ellis
P304
P356
10.1016/J.CCT.2007.10.008
P407
P577
2007-11-12T00:00:00Z